Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
This article was originally published in The Pink Sheet Daily
Executive Summary
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.